Introduction
Multiple sclerosis (MS) is an immune-mediated, demyelinating disease of the central nervous system. 1 The inflammatory element responds to lymphocyte, notably B cell, depleting agents. 2 Alemtuzumab is one of the most-effective treatments for relapsing MS, 3, 4 but it causes delayed B-cell autoimmunities in a significant number of people with MS. 5 We have postulated that this is a consequence of B-cell hyper-repopulation in the relative absence of Tcell regulation. 6 The loss of immune tolerance may also allow anti-alemtuzumab responses to form, 6 which have been reported to be of no consequence to safety or efficacy. 3, 4, 7 Alemtuzumab (CAMPATH-1H) was the first humanized antibody, which was generated to reduce the immunogenicity of the parent CD52-specific rat monoclonal antibody. 8 A low anti-globulin response was inferred to occur from the phase II study report in people with MS, with only 1 in 208 people (0Á5%) having binding antibodies (BAbs), above a predefined limit, within 12 months. 9 Even within the phase III trial reports in MS, only 29% of people were reported to have BAbs at 12 months. 3, 4 However, analysis of data from rheumatoid arthritis (63% BAbs after first infusion), 10 other MS studies, 11 and importantly the regulatory submission to the European Medicines Agency (EMA) containing the phase III trial results, showed that a substantial number of people with MS (579/811 (71Á5%) produced drug-specific antibody responses within 12 months. 6 It was evident that alemtuzumab induced a high-frequency [667/789 (84Á9%) within 24 months] and high-titre (up to 6 553 600) BAb response that was boosted by repeated cycles of treatment. 6 Surprisingly, it was also found that 623/667 (93Á4% within 24 months) of those people with binding antibodies also produced neutralizing antibodies (NAbs). 6 The occurrence of NAbs was not disclosed in the pivotal trial reports 3, 4 and their importance was also dismissed in a meeting report. 7 In addition, no effect on depletion was reported in people with MS requiring multiple cycles of alemtuzumab in phase II and phase III extension studies. 12, 13 Although it is possible that NAbs are not significant at the population level, it was hypothesized that NAbs would be important for some individuals, particularly those requiring additional alemtuzumab infusions, 5, 13 as NAbs may become persistent in some people. 6 
Materials and methods

Clinical trial reports
Redacted copies of the regulatory submission of the Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis, study one (CARE-MS I. NCT00530348
3 ) and two (CARE-MS II. NCT0054805 4 ), were supplied by the EMA. 6 The trials were performed in people with MS who were treatment-naive (CARE-MS I) or who had previously been treated (CARE-MS II) with interferon-b or glatiramer acetate. The data presented here only concern the 12 mg/day alemtuzumab dose, used in clinical practice. This information was derived from the tabulated documents supplied since Q2 2016. Tabulated data concerning BAbs and NAbs during MS-CARE II have not yet been supplied. The primary raw data were not supplied by the EMA and requests to access data on antibody responses, via the clinicalstudydatarequest.com website, of which Sanofi is a sponsor, have not yet been supported.
Audit
An audit of 126 people with MS receiving alemtuzumab as part of their clinical care at The Royal London Hospital (Barts Health NHS Trust) was performed to determine their lymphocyte counts following five daily 12-mg alemtuzumab infusions (first cycle) or three 12-mg infusions (second cycle). Cell numbers were monitored as part of standard care. Analysis of these data did not require ethical review. Informed consent was obtained to report individual case reports.
Results
At the population level, alemtuzumab-specific antibodies do not influence the efficacy of alemtuzumab during the first two treatment cycles Analysis of the tabulated, unpublished CARE-MS I 3 data provided by the EMA was consistent with published statements 3,4,7 that alemtuzumab-specific antibodies did not impact on lymphocyte depletion (Table 1a) , clinical efficacy (Table 1b) or safety (Table 1c; see Supplementary  material, Table S1 ). This was perhaps not surprising because, at the time of infusion, 0% of the participants had NAbs before the first cycle of antibodies and only 5/ 789 (0Á6% from CARE-MS I and II) had NAbs before the second cycle of antibody. Hence, at the population level, the presence of drug-specific antibodies appeared to be of no concern to the regulators within the EMA. 14 However, interpretation of an online scatter diagram ( Fig. 1 ) from an EMA assessment report, 14 which related lymphocyte number to time from infusion and alemtuzumab-specific antibody status, suggested two previously unreported issues. These are particularly evident when focusing on the first month after treatment, when lymphocyte depletion would not be masked by the rapid B-cell repopulation that occurs following alemtuzumab infusion. 6 It appears that there are: (i) alemtuzumab antibody-negative individuals who do not deplete, or poorly deplete, their lymphocytes, and (ii) individuals who produce alemtuzumab-specific antibodies (Fig. 1) , who do not deplete or poorly deplete lymphocytes.
14 Alemtuzumab-specific antibodies can influence the efficacy of alemtuzumab at the individual level
The data incorporated in the online EMA report (Fig. 1) , are consistent with the supplied data from CARE-MS I studies, which indicated that the depletion of lymphocytes was more marked in antibody-negative individuals (Baseline 2Á01 AE 0Á64 9 10 9 /l, n = 91; 0Á22 AE 0Á32 cells 9 10 9 /l, n = 45; 1 month after cycle 2) compared with ever-antibody-positive individuals (BAb only: Baseline 2Á08 AE 0Á77 9 10 9 /l n = 68; 0Á42 AE 0Á24 9 10 9 /l n = 14. BAbs & NAbs: Baseline 2Á09 AE 0Á61 9 10 9 /l, n = 210; 0Á37 AE 0Á22 9 10 9 /l, n = 283) ( Table 2) . However, without access to the individualized data, it is not possible to determine whether: (i) this was statistically significant, and (ii) the reduced-depletion was due to NAbs or an inherent characteristic of people generating anti-drug antibodies, given differences were evident 1 month after the first cycle (Table 2 ). Nevertheless, inspecting responses before and after alemtuzumab reveals that pre-cycle alemtuzumab NAbs did affect lymphocyte depletion at the individual level ( Table 3) . Examination of immunophenotyping, 1 month after the second infusion cycle, demonstrated that one individual with a hightitre response had failed to adequately deplete (Table 3 ). This raises concerns that neutralization responses would become more problematic during and following a third treatment cycle, as 623/789 (79Á0%; titre 30-102, 400) people had made a BAb response and 239/764 (31Á3%; titre 20-640) had a persistent NAb response at 24 months from treatment onset. 14 Indeed a blunted lymphocyte depletion response was seen following a third treatment cycle in an individual, in the MS-CARE extension programme, who received multiple treatment cycles due to disease activity (see Supplementary material, Fig. S1 ). A clinical relapse triggered a fourth cycle about 20 months later. Although depletion was comparable to the first and second treatment cycles, inflammatory MS activity occurred, triggering a fifth infusion, which induced limited depletion. Following requests about information relating to antibody neutralization. The manufacturer confirmed the presence of BAbs and the presence of NAbs (maximum titre = 200), which were boosted with each cycle. This alerted us to the fact that NAbs occurred, in part prompting our investigations. Although this individual was clearly depleting, it was possible that NAbs were contributing to treatment failure. Indeed an online search of meeting presentations revealed that 2/6 (33Á3%) people who received at least three infusions of alemtuzumab before being switched to fingolimod, showed a relative lack of depletion upon the third treatment cycle, 15 suggesting that some people may generate a neutralizing response that prevents depletion.
This prompted us to audit the lymphocyte levels of people with MS treated with alemtuzumab in our centre in the post-marketing setting (see Supplementary material, Fig. S2 ). All 57 people with who received two cycles of treatment had lymphocyte depletion following infusion cycle 1 and 2. The lymphocytes were depleted from 2Á21 AE 1Á06 9 10 9 cells/l to 0Á27 AE 0Á21 9 10 9 cells/l (P < 0Á001 compared with baseline) at month 1 and 0Á36 AE 0Á20 9 10 9 cells/l (P = 0Á001 compared with baseline) at month 13, 1 month after the second cycle. However, paired analysis indicated that there was significantly (P = 0Á004) more depletion after the first infusion compared with the second infusion cycle, perhaps consistent with more antibody being infused on the first cycle (60 mg) compared with subsequent (36 mg) cycles. It was found that 7/57 people did not deplete below 0Á7 9 10 9 cells/l after the second infusion cycle and one person depleted by only 36Á4% compared with month 0, despite a depletion of over 80% following the first infusion. However, the status of alemtuzumab-specific antibodies was unknown. Outside the CARE MS extension The presence of binding (BAb) and Binding and neutralizing antibodies (NAb) was assessed as being present or absent during each cycle of treatment of alemtuzumab. The results were extracted from tabulated data within the EMA dataset. They represent the mean and standard deviation, the number and annualized relapse rate and 95% confidence intervals. The mean and standard deviation of T2 lesions and the number of adverse events and (percentage). trial participants, people with MS generally do not receive a third treatment cycle, though there is some inconsistency in provision of the drug across the National Health Service within the UK. People with disease breakthrough were often switched to other disease-modifiying treatments. The data suggest that a few individuals fail to deplete, consistent with the generation of a NAb response.
Some individuals do not develop leucocyte depletion following alemtuzumab-treatment
Although NAbs may cause lack of response to alemtuzumab, the EMA report 14 data indicated that there may also be alemtuzumab antibody-negative individuals who fail to deplete, or deplete poorly (Fig. 1) . We were able to identify such cases in the EMA data set supplied. At baseline there were 2Á07 AE 0Á65 9 10 9 cells/l (n = 369; range 0Á93-5Á83 9 10 9 cells/l) lymphocytes. There was depletion within 1 month after alemtuzumab (0Á27 AE 0Á22 9 10 9 cells/l; n = 361) but the upper values of the range (0Á02 9 10 9 -2Á00 9 10 9 cells/l) indicated that some people either did not deplete or depleted poorly.
In the audit at The Royal London Hospital, 126 people with MS who received at least one dose of alemtuzumab (see Supplementary material, Fig. S2 ) had 2Á05 AE 0Á89 9 10 9 lymphocytes/l (range 0Á4 9 10 9 -6Á2 9 10 9 cells/l) at baseline and depleted to 0Á27 AE 0Á19 9 10 9 lymphocytes/l (range 0Á0 9 10 9 -1Á0 9 10 9 cells/l) 1 month later. Only 3/126 people did not deplete below 0Á7 9 10 9 /l. Two people depleted by < 50% after first administration, although one of these was lymphopenic at baseline. Of note, the individual who was a poor-depleter (11Á1%) had been treated with fingolimod, a risk factor for lack of alemtuzumab activity, 16 before switching to alemtuzumab. The presence of binding (BAb) and Binding and neutralizing antibodies (NAb) was assessed as being present or absent during each cycle of treatment of alemtuzumab. The results represent the mean and standard deviation of cells 9 10 9 /l at various times post infusion at baseline and at 12 months or the number of adverse events and (percentage). However other individuals were identified who depleted very poorly upon the first infusion, but had not used fingolimod previously. Their most recent therapy had been dimethyl fumarate. In one individual, their baseline white blood cell count was 7Á6 9 10 9 cells/l and this only decreased to 7Á0 9 10 9 /l 1 month after alemtuzumab infusion and their lymphocyte count went from 2Á0 9 10 9 cells/l to 2Á58 9 10 9 cells/l 1 month after alemtuzumab. In another individual, poor depletion was also evident (Fig. 2) . Hence, there are people with MS who do not deplete, or deplete poorly, following alemtuzumab treatment. Further clinical investigations into the causes of this can be made once ethical approval for such research is acquired.
Discussion
Although alemtuzumab was the first humanized antibody designed to reduce the immunogenicity of therapeutic rodent antibodies, 8 it is clear that its biology prevents this from being adequately achieved and it is, perhaps, rather poor at limiting immunogenicity. 6 It is well understood that NAb responses lead to failure of therapeutic drugs, including therapeutic antibodies, 17 as indicated here following alemtuzumab treatment. CD52-specific antibodies deplete CD4 regulatory T cells and CD8 suppressor cells and appear to block immunological tolerance induction, 6 ,18 at a time of immature B-cell hyper-population, seen in the blood. 6 This may create the environment for secondary B-cell autoimmunities that occur with high frequency as a consequence of alemtuzumab treatment and may also create an environment for NAb production. 6 Although alemtuzumab depletes peripheral blood leucocytes, it appears to use antibody-dependent cellular cytotoxicity as a central depleting mechanism and may purge the lymphoid tissues, notably the bone marrow, less effectively, as seen in CD52-depleting antibody in human CD52-transgenic and wild-type mice. [18] [19] [20] Therefore, antiglobulin responses may be generated during the 5-day infusion period when high-titre blood concentrations are present and account for the high frequency of BAbs and NAbs produced within a month of first infusion. 6 The influence of BAbs and NAbs is not a major issue within the first 2 years of the trial analysis examined by the regulators.
14 However, the concern should be that alemtuzumab neutralization may be more of a problem following subsequent cycles. At the population level, depletion occurred with each treatment in the MS-CARE extension study, 13 consistent with earlier studies (n = 108 12 ), without mention of non-depleters. However, as reported here, there is no doubt that NAbs have led to some people being repeatedly treated with agents with limited efficacy 15 and they do become problematic for some individuals. 21, 22 The failure to adequately report this issue has probably exposed people to the unnecessary risks of the procedures and risks of disease reactivation due to lack of efficacy. Indeed our own experience prompted us to investigate and expose 16 the occurrence of alemtuzumab neutralization. This study indicates that at the individual level NAbs may indeed be very important, and shows that it is critical that lymphocyte-depleting potential is monitored. This could easily be scheduled due to the requirement for monthly safety blood tests and the titres of antibodies should be monitored before re-infusion, in particular in relation to the third, fourth and fifth treatment cycles. In addition, BAbs may also contribute to loss of function of alemtuzumab. They may serve to augment cross-linking of CD52 that can expand CD52-deficient lymphocytes. 23 These CD52-deficient cells occur following alemtuzumab infusion and can persist for months within the B-cell compartment and for years within the T-cell compartment. 24 Further work will be needed to determine pretreatment levels that contribute to physical antibody neutralization and lack of treatment response.
In addition to the generation of NAbs, it is also evident that some people do not deplete/delete well on first infusion. It is interesting that people destined to make alemtuzumab-specific antibodies appeared to deplete lymphocytes less well than those who did not make antibodies. This occurred even after the first infusion and probably before NAbs would influence the outcome, suggesting a genetic predisposing influence. Analysis of over 60 000 exomes has not indicated loss of function variants of CD52. 25 There are, however, two common single nucleotide polymorphisms (SNP; rs1071849 and rs17645) in the 3 0 untranslated region that are in linkage disequilibrium (allele frequency in Europeans = 0Á7541 25 ), which are suggested to impact the efficacy of the glycosylphosphatidylinositol anchor in CD52 to influence responses to alemtuzumab, in some circumstances. 26, 27 Furthermore, Latino people have a common SNP (rs77928789; allele frequency = 0Á1931) in the 5 0 untranslated region. 25 Whether these alleles influence expression of CD52 is unclear. In addition, there are Fc receptor (FCGR3A, SNP rs396991 and FCGR2A, SNP rs1801274) variants that influence affinity for human IgG1 and affect efficacy of antibody-dependent cellular cytotoxicity, [28] [29] [30] which is reported to be an important depletion mechanism of alemtuzumab. 19 Although these Fc receptor variants did not affect alemtuzumab (CAMPATH-1H)-induced depletion at doses used to treat cancer, 31 this dose is significantly higher than the alemtuzumab (Lemtrada) formulation used in MS. Therefore, these genetic variants may be relevant in MS, as the Fc receptor depletion influences are known to be antibody dose-dependent, as seen with rituximab-induced depletion. 29, 32 It will be important to determine whether these alleles are important in depletion caused by alemtuzumab in MS, as it may influence switching to other IgG1 treatments or non-antibody alternatives.
Alternatively it has also been suggested that prior use of fingolimod, to sequester lymphocytes into lymphoid tissue and bone marrow, may block the activity of alemtuzumab and allow more rapid repopulation. 16 Therefore, it is of interest that one of the poor depleters reported here was treated with fingolimod prior to alemtuzumab. However, the people in the MS-CARE studies were naive with respect to fingolimod and therefore poor depletion in some people with MS has alternative explanations and requires further investigation.
Although it is evident that alemtuzumab is a useful treatment, and despite being a potent T-cell and B-cell depletion agent, alemtuzumab is not immune to the problems associated with NAbs. Our study suggests that it is important to actively monitor lymphocyte depletion potential to determine whether individual people with MS are, perhaps genetically, resistant to alemtuzumab depletion, or perhaps whether there is resistance to IgG1 depletion. It will also be important to monitor whether high-titre NAbs are present before re-infusion of additional treatment cycles. This may affect decisions to retreat or switch treatment and may influence which treatments people are switched to.
It is likely that the frequency of non-depletors/poor depletors on first and subsequent treatment cycles and the pre-treatment titre of anti-alemtuzumab antibodies that are associated with loss of depletion function is known or readily accessible by the manufacturer. This is because people with MS were immunophenotyped during the original MS-CARE studies, 6 and many people with MS (n = 742/811) entered the CARE-MS extension studies and were immune-phenotyped. 13 Many people with MS (n = 412) received no re-treatment or other diseasemodifiying treatments., but some people received a third (n = 156), fourth (n = 48) or fifth (n = 8) treatment cycle. 13 Alternatively, examination and compilation of post-marketing data will allow some of these issues to be investigated. However, this is yet another example of why it is important that full and unrestricted access to all anonymized clinical trial data should be granted within a reasonable time frame, both to incentivize companies to publish their data, and to ensure that efficacy and, importantly, safety issues can be investigated independently. This information should be deposited, in an accessible format, prior to and as part of initial, and subsequent, regulatory approval processes. 
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